S&P 500   3,390.59 (+0.60%)
DOW   29,391.22 (+0.54%)
QQQ   237.14 (+1.03%)
AAPL   323.94 (+1.55%)
FB   217.29 (-0.23%)
MSFT   187.16 (-0.04%)
GOOGL   1,528.53 (+0.60%)
AMZN   2,179.16 (+1.09%)
CGC   21.74 (-0.91%)
NVDA   312.92 (+5.51%)
BABA   222.18 (+0.75%)
MU   59.21 (+2.53%)
GE   12.86 (+0.86%)
TSLA   926.00 (+7.88%)
AMD   59.08 (+3.85%)
T   38.46 (+0.52%)
ACB   1.70 (+3.66%)
F   8.01 (-0.62%)
NFLX   387.46 (-0.08%)
PRI   136.41 (+0.58%)
BAC   34.80 (+1.52%)
DIS   141.28 (+1.54%)
GILD   66.99 (-0.04%)
S&P 500   3,390.59 (+0.60%)
DOW   29,391.22 (+0.54%)
QQQ   237.14 (+1.03%)
AAPL   323.94 (+1.55%)
FB   217.29 (-0.23%)
MSFT   187.16 (-0.04%)
GOOGL   1,528.53 (+0.60%)
AMZN   2,179.16 (+1.09%)
CGC   21.74 (-0.91%)
NVDA   312.92 (+5.51%)
BABA   222.18 (+0.75%)
MU   59.21 (+2.53%)
GE   12.86 (+0.86%)
TSLA   926.00 (+7.88%)
AMD   59.08 (+3.85%)
T   38.46 (+0.52%)
ACB   1.70 (+3.66%)
F   8.01 (-0.62%)
NFLX   387.46 (-0.08%)
PRI   136.41 (+0.58%)
BAC   34.80 (+1.52%)
DIS   141.28 (+1.54%)
GILD   66.99 (-0.04%)
S&P 500   3,390.59 (+0.60%)
DOW   29,391.22 (+0.54%)
QQQ   237.14 (+1.03%)
AAPL   323.94 (+1.55%)
FB   217.29 (-0.23%)
MSFT   187.16 (-0.04%)
GOOGL   1,528.53 (+0.60%)
AMZN   2,179.16 (+1.09%)
CGC   21.74 (-0.91%)
NVDA   312.92 (+5.51%)
BABA   222.18 (+0.75%)
MU   59.21 (+2.53%)
GE   12.86 (+0.86%)
TSLA   926.00 (+7.88%)
AMD   59.08 (+3.85%)
T   38.46 (+0.52%)
ACB   1.70 (+3.66%)
F   8.01 (-0.62%)
NFLX   387.46 (-0.08%)
PRI   136.41 (+0.58%)
BAC   34.80 (+1.52%)
DIS   141.28 (+1.54%)
GILD   66.99 (-0.04%)
S&P 500   3,390.59 (+0.60%)
DOW   29,391.22 (+0.54%)
QQQ   237.14 (+1.03%)
AAPL   323.94 (+1.55%)
FB   217.29 (-0.23%)
MSFT   187.16 (-0.04%)
GOOGL   1,528.53 (+0.60%)
AMZN   2,179.16 (+1.09%)
CGC   21.74 (-0.91%)
NVDA   312.92 (+5.51%)
BABA   222.18 (+0.75%)
MU   59.21 (+2.53%)
GE   12.86 (+0.86%)
TSLA   926.00 (+7.88%)
AMD   59.08 (+3.85%)
T   38.46 (+0.52%)
ACB   1.70 (+3.66%)
F   8.01 (-0.62%)
NFLX   387.46 (-0.08%)
PRI   136.41 (+0.58%)
BAC   34.80 (+1.52%)
DIS   141.28 (+1.54%)
GILD   66.99 (-0.04%)
Log in

NASDAQ:VBLT - Vascular Biogenics Stock Price, Forecast & News

$1.40
+0.03 (+2.20 %)
(As of 02/19/2020 12:18 PM ET)
Today's Range
$1.37
Now: $1.40
$1.41
50-Day Range
$1.19
MA: $1.41
$1.57
52-Week Range
$0.93
Now: $1.40
$1.90
Volume29,656 shs
Average Volume101,647 shs
Market Capitalization$50.08 million
P/E RatioN/A
Dividend YieldN/A
Beta0.63
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VBLT
Previous SymbolNASDAQ:VBLX
CUSIPN/A
Phone972-8993-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$580,000.00
Book Value$1.48 per share

Profitability

Net Income$-20,460,000.00
Net Margins-3,050.43%

Miscellaneous

Employees39
Market Cap$50.08 million
Next Earnings Date3/26/2020 (Estimated)
OptionableOptionable

Receive VBLT News and Ratings via Email

Sign-up to receive the latest news and ratings for VBLT and its competitors with MarketBeat's FREE daily newsletter.


Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd (NASDAQ:VBLT) issued its quarterly earnings results on Thursday, November, 14th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.14). The biopharmaceutical company earned $0.08 million during the quarter, compared to analysts' expectations of $0.24 million. Vascular Biogenics had a negative net margin of 3,050.43% and a negative return on equity of 37.19%. View Vascular Biogenics' Earnings History.

When is Vascular Biogenics' next earnings date?

Vascular Biogenics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Vascular Biogenics.

What price target have analysts set for VBLT?

5 equities research analysts have issued 12-month target prices for Vascular Biogenics' shares. Their forecasts range from $2.00 to $3.25. On average, they anticipate Vascular Biogenics' stock price to reach $2.75 in the next twelve months. This suggests a possible upside of 95.6% from the stock's current price. View Analyst Price Targets for Vascular Biogenics.

What is the consensus analysts' recommendation for Vascular Biogenics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vascular Biogenics.

What are Wall Street analysts saying about Vascular Biogenics stock?

Here are some recent quotes from research analysts about Vascular Biogenics stock:
  • 1. According to Zacks Investment Research, "Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. " (1/28/2020)
  • 2. Chardan Capital analysts commented, "We understand the colon cancer trial will be a single- arm open label design, providing the possibility of an early look at efficacy signals, with data anticipated in 2020. We expect more details on these programs as the GBM and colon cancer trials begin." (5/16/2019)

Has Vascular Biogenics been receiving favorable news coverage?

News stories about VBLT stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vascular Biogenics earned a daily sentiment score of -1.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Vascular Biogenics.

Are investors shorting Vascular Biogenics?

Vascular Biogenics saw a increase in short interest in January. As of January 31st, there was short interest totalling 52,500 shares, an increase of 21.2% from the January 15th total of 43,300 shares. Based on an average daily volume of 81,600 shares, the short-interest ratio is presently 0.6 days. Currently, 0.2% of the shares of the stock are short sold. View Vascular Biogenics' Current Options Chain.

Who are some of Vascular Biogenics' key competitors?

What other stocks do shareholders of Vascular Biogenics own?

Who are Vascular Biogenics' key executives?

Vascular Biogenics' management team includes the folowing people:
  • Prof. Dror Harats, CEO & Director (Age 62)
  • Mr. Amos Ron, CFO & Company Sec. (Age 64)
  • Dr. Erez Feige, VP of Bus. Operations (Age 45)
  • Dr. Eyal Breitbart, VP of Research & Operations (Age 52)
  • Dr. Naamit Sher, VP of Drug Devel. & Regulatory Affairs (Age 65)

Who are Vascular Biogenics' major shareholders?

Vascular Biogenics' stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.10%).

Which institutional investors are buying Vascular Biogenics stock?

VBLT stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy shares of Vascular Biogenics?

Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $1.41.

How big of a company is Vascular Biogenics?

Vascular Biogenics has a market capitalization of $50.44 million and generates $580,000.00 in revenue each year. The biopharmaceutical company earns $-20,460,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Vascular Biogenics employs 39 workers across the globe.View Additional Information About Vascular Biogenics.

What is Vascular Biogenics' official website?

The official website for Vascular Biogenics is http://www.vblrx.com/.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The biopharmaceutical company can be reached via phone at 972-8993-5000 or via email at [email protected]


MarketBeat Community Rating for Vascular Biogenics (NASDAQ VBLT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  252 (Vote Outperform)
Underperform Votes:  282 (Vote Underperform)
Total Votes:  534
MarketBeat's community ratings are surveys of what our community members think about Vascular Biogenics and other stocks. Vote "Outperform" if you believe VBLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Featured Article: Initial Coin Offering (ICO)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel